Aebi S, Assereto R, Lauterburg BH. 1991. High-dose intravenous glutathione in man. Pharmacokinetics and effects on cysteine in plasma and urine. European Journal of Clinical Investigation. 21(1):103-10. https://www.ncbi.nlm.nih.gov/pubmed/1907548/
Davids LM, Van Wyk JC, Khumalo NP. 2016. Intravenous glutathione for skin lightening: Inadequate safety data. South African Medical Journal. 106(8):782-6. https://www.ncbi.nlm.nih.gov/pubmed/27499402
Fukugawa NK, Ajami AM, Young VR. 1996. Plasma methionine and cysteine kinetics in response to an intravenous glutathione infusion in adult humans. American Journal of Physiology. 270(2 Pt 1):E209-14. https://www.ncbi.nlm.nih.gov/pubmed/8779940
Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D. 2009. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson’s disease. Movement Disorders. 24(7):979-83. https://www.ncbi.nlm.nih.gov/pubmed/19230029
Kern JK, Geier DA, Adams JB, Garver CR, Audhya T, Geier MR. 2011. A clinical trial of glutathione supplementation in autism spectrum disorders. Medical Science Monitor. 17(12):CR677-682. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3628138/
King LA, Horak FB. 2009. Delaying mobility disability in people with Parkinson disease using a sensorimotor agility exercise program. Physical Therapy. 89(4):384-393. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2664996/
Marco EJ, Hinkley LBN, Hill SS, Nagarajan SS. 2011. Sensory processing in autism: A review of neurophysiologic findings. Pediatric Research. 69(5 Pt 2):48R-54R. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086654/
Otto M, Magurs T, Langland JO. 2017. The use of intravenous glutathione for symptom management of Parkinson’s disease: A case report. Alternative Therapies in Health and Medicine. https://www.ncbi.nlm.nih.gov/pubmed/29101773
Pizzorno J. 2014. Glutathione! Integrative Medicine: A Children’s Journal. 13(1):8-12. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4684116/